[Advances in antibody-conjugating drugs in prostate cancer: applications and challenges]
1Department of Urology, the Second Xiangya Hospital of Central South University, Changsha 410012, China.
Abstract:
In recent years, significant progress has been made in the structural optimization and mechanistic research of antibody-drug conjugates (ADC), with multiple clinical trials for prostate cancer underway and demonstrating broad clinical application prospects. Compared with traditional chemotherapy and immunotherapy, ADC combines the targeting specificity of monoclonal antibodies with the potent tumor-killing ability of chemotherapeutic drugs, offering potential therapeutic options for prostate cancer patients. Currently, four prostate-specific membrane antigen-targeted ADC have entered the clinical trial phase, but their clinical efficacy and safety profiles exhibit significant differences. Additionally, the identification of novel molecular biomarkers such as STEAP1, TROP2, and B7-H3 has provided potential targets for the development of the next generation of prostate cancer ADC, with relevant candidate drugs having progressed to clinical trials and their research outcomes highly anticipated. Although no ADC has been approved for clinical treatment of prostate cancer, in-depth analysis of the current challenges and future development directions in ADC research will provide theoretical support and innovative insights for advancing these agents in prostate cancer research.
Insights
Antibody-drug conjugates (ADCs) show promise for prostate cancer treatment by combining targeted antibody delivery with potent chemotherapy. Ongoing clinical trials explore new targets like STEAP1, TROP2, and B7-H3 for improved efficacy and safety.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Antibody-drug conjugates (ADCs) represent a significant advancement in cancer therapy, particularly for prostate cancer.
- ADCs leverage the specificity of monoclonal antibodies to deliver potent cytotoxic drugs directly to tumor cells, overcoming limitations of traditional treatments.
Purpose of the Study:
- To review the current progress in antibody-drug conjugate (ADC) development for prostate cancer.
- To analyze the clinical efficacy and safety profiles of existing ADCs targeting prostate-specific membrane antigen (PSMA).
- To explore novel molecular targets and future directions for next-generation prostate cancer ADCs.
Main Methods:
- Review of recent literature on ADC structural optimization and mechanistic research.
- Analysis of clinical trial data for PSMA-targeted ADCs in prostate cancer.
- Identification and evaluation of emerging molecular biomarkers (STEAP1, TROP2, B7-H3) for ADC development.
Main Results:
- Multiple PSMA-targeted ADCs are in clinical trials for prostate cancer, showing varied efficacy and safety.
- Novel biomarkers like STEAP1, TROP2, and B7-H3 are emerging as promising targets for next-generation ADCs.
- Despite no current approvals, ADCs demonstrate significant potential for prostate cancer treatment.
Conclusions:
- ADCs offer a promising therapeutic strategy for prostate cancer, distinct from chemotherapy and immunotherapy.
- Continued research into novel targets and optimization of ADC design is crucial for clinical success.
- Further investigation into ADC challenges and future directions will guide the development of more effective treatments for prostate cancer.
